Finance

Lists
ROSSARI:NSE
Rossari Biotech Ltd
435,10 INR
+1,21%
(+5,20) 1D
13-ноя., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ROSSARI...
Open
432,60 INR
High
440,85 INR
Low
428,35 INR
Mkt. cap
24,15 млд
Avg. vol.
81,15 миң
Volume
79,56 миң
Dividend
0,11%
Quarterly dividend
0,12 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
15,79
52-wk high
639,40 INR
52-wk low
375,00 INR
EPS
27,56 INR
No. of employees
585
Open
432,60 INR
High
440,85 INR
Low
428,35 INR
Mkt. cap
24,15 млд
Avg. vol.
81,15 миң
Volume
79,56 миң
Dividend
0,11%
Quarterly dividend
0,12 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
15,79
52-wk high
639,40 INR
52-wk low
375,00 INR
EPS
27,56 INR
No. of employees
585
News stories
From web sources and news partners
Profile
Rossari Biotech is an Indian chemical manufacturing company with a focus on specialty chemicals. It is also engaged in production of specialty enzymes and chemicals in India that is used in the pharmaceuticals, paper, construction, textiles, nutrition and animal health industries. The company was started in 2003 as a partnership firm titled Rossari Labtech and was incorporated into a company in 2009 and was renamed as Rossari Biotech. It has two R&D facilities, one at Silvassa manufacturing facility and the second in Dahej. Wikipedia
About Rossari Biotech Ltd
CEO-
Employees585
Founded2009-ж., 10-авг.
Headquarters-
SectorMaterials
IndustrySpeciality chemicals
Last report
2026-ж., 19-окт.
Fiscal period
Q2 2027
7,02 INR / 5,90 INR
+18,98%beat
Revenue / Est. (INR)
6,98 млд / 6,79 млд
+2,69%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
5,82 млд
6,85 млд
6,97 млд
6,98 млд
Cost of goods sold
4,01 млд
5,04 млд
4,91 млд
4,77 млд
Cost of revenue
4,01 млд
5,04 млд
4,91 млд
4,77 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
402,56 млн
463,26 млн
440,44 млн
436,16 млн
Operating expense
1,32 млд
1,44 млд
1,51 млд
1,63 млд
Total operating expenses
5,32 млд
6,48 млд
6,42 млд
6,41 млд
Operating income
492,59 млн
369,04 млн
550,05 млн
568,78 млн
Other non operating income
5,09 млн
-27,71 млн
31,87 млн
5,99 млн
EBT including unusual items
425,01 млн
642,43 млн
476,72 млн
492,69 млн
EBT excluding unusual items
425,01 млн
437,87 млн
476,72 млн
492,69 млн
Income tax expense
97,27 млн
182,76 млн
125,77 млн
103,62 млн
Effective tax rate
22,89%
28,45%
26,38%
21,03%
Other operating expenses
717,50 млн
736,59 млн
817,11 млн
896,62 млн
Net income
327,74 млн
459,67 млн
350,95 млн
389,07 млн
Net profit margin
5,63%
6,71%
5,03%
5,58%
Earnings per share
5,91
8,29
6,33
7,02
Interest and investment income
-
13,51 млн
-
-
Interest expense
-76,65 млн
-90,59 млн
-109,77 млн
-86,77 млн
Net interest expenses
-76,65 млн
-77,08 млн
-109,77 млн
-86,77 млн
Depreciation and amortization charges
196,14 млн
235,28 млн
256,15 млн
300,96 млн
EBITDA
645,98 млн
544,80 млн
725,80 млн
847,34 млн
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору